Literature DB >> 22804571

T-cell-independent antitumor effects of CD40 ligation.

Alexander L Rakhmilevich1, Kory L Alderson, Paul M Sondel.   

Abstract

CD40 ligation has been shown to induce antitumor effects in mice and cancer patients. Most of the studies have focused on the ability of an agonistic anti-CD40 mAb to either directly kill CD40-positive tumor cells or activate T-cell immune responses. In this review the authors focus on the ability of CD40 ligation to activate antitumor effector mechanisms of the cells of innate immunity such as macrophages and NK cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22804571      PMCID: PMC3537496          DOI: 10.3109/08830185.2012.698337

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  88 in total

1.  Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.

Authors:  J G Turner; A L Rakhmilevich; L Burdelya; Z Neal; M Imboden; P M Sondel; H Yu
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

2.  Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells.

Authors:  Kei Tomihara; Kazunori Kato; Yukari Masuta; Kiminori Nakamura; Toshihiro Tanaka; Hiroyoshi Hiratsuka; Hirofumi Hamada
Journal:  Int J Cancer       Date:  2007-04-01       Impact factor: 7.396

3.  Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.

Authors:  Timothy S Lewis; Renee S McCormick; Kim Emmerton; Jeffrey T Lau; Shang-Fan Yu; Julie A McEarchern; Iqbal S Grewal; Che-Leung Law
Journal:  Clin Cancer Res       Date:  2011-05-24       Impact factor: 12.531

4.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

5.  Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.

Authors:  Qiao Li; Xiangming Lao; Qin Pan; Ning Ning; Ji Yet; Yingxin Xu; Shengping Li; Alfred E Chang
Journal:  Clin Cancer Res       Date:  2011-06-20       Impact factor: 12.531

6.  Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.

Authors:  Fernando Aranda; Diana Llopiz; Nancy Díaz-Valdés; José Ignacio Riezu-Boj; Jaione Bezunartea; Marta Ruiz; Marta Martínez; Maika Durantez; Cristina Mansilla; Jesús Prieto; Juan José Lasarte; Francisco Borrás-Cuesta; Pablo Sarobe
Journal:  Cancer Res       Date:  2011-03-14       Impact factor: 12.701

7.  CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.

Authors:  Ilia N Buhtoiarov; Hillary Lum; Gideon Berke; Donna M Paulnock; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

8.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Macrophage accumulation in murine ascites tumors. I. Cytoxan-induced dominance of macrophages over tumor cells and the anti-tumor effect of endotoxin.

Authors:  E S Dye; R J North
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more
  23 in total

1.  Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Authors:  Xiaoyi Qu; Mildred A R Felder; Zulmarie Perez Horta; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Int Immunopharmacol       Date:  2013-11-04       Impact factor: 4.932

2.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 3.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

4.  Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.

Authors:  Alexander L Rakhmilevich; Mildred Felder; Lauren Lever; Jacob Slowinski; Kayla Rasmussen; Anna Hoefges; Tyler J Van De Voort; Hans Loibner; Alan J Korman; Stephen D Gillies; Paul M Sondel
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

5.  Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.

Authors:  Yongyu Shi; Mildred A R Felder; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Mol Immunol       Date:  2015-03-28       Impact factor: 4.407

Review 6.  Novel Targets for the Treatment of Melanoma.

Authors:  Lara Ambrosi; Shaheer Khan; Richard D Carvajal; Jessica Yang
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

Review 7.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

8.  Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.

Authors:  Mauricio Urquiza; Johanna Melo-Cardenas; Robier Aguillon; Thomas J Kipps; Januario E Castro
Journal:  Hum Gene Ther       Date:  2015-01       Impact factor: 5.695

Review 9.  Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.

Authors:  Ondrej Uher; Veronika Caisova; Per Hansen; Jan Kopecky; Jindrich Chmelar; Zhengping Zhuang; Jan Zenka; Karel Pacak
Journal:  Semin Oncol       Date:  2019-11-06       Impact factor: 4.929

10.  Deploying myeloid cells against myeloma.

Authors:  Jeffrey L Jensen; Chelsea Hope; Fotis Asimakopoulos
Journal:  Oncoimmunology       Date:  2015-12-10       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.